Torrent Pharmaceuticals Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Mid Cap

Revenue from operations rose 10.34% year on year (YoY) to Rs 2,859 crore in the quarter ended 30 June 2024.

Profit before tax stood at Rs 656 crore in June 2024 quarter, up 23.54% from Rs 433 crore posted in same quarter last year.

Operating EBITDA stood at Rs 904 crore in Q1 FY25, registering a growth of 14% as against Rs 791 crore reported in Q1 FY24.

The company's India revenue grew by 15% YoY to Rs 1,635 crore in Q1 FY25, led by outperformance in focus therapies. As per All India Organization of Chemists & Druggists (AIOCD) secondary market data, IPM growth for the quarter was 8%. Torrent’s chronic business grew at 14% versus IPM growth of 8%, driven by strong revival in cardiac divisions and continued traction in anti-diabetes (OAD) new launches.

Torrent Pharma's Brazil revenue rose by 3% to Rs 196 crore and on constant currency terms revenues was up by 8% at R$ 123 million. As per IQVIA, market growth for the quarter was 11%. Primary sales were impacted by severe floods in the province of Rio Grande do Sul in April and May 2024.

The Germany revenue stood at Rs 284 crore, by 10%. Constant currency revenue at Euro 31 million was up by 9%. Growth momentum continued with incremental tender wins coupled with incremental sales from Q2 onwards.

The company's US revenue stood at Rs 259 crore in Q1 FY25, down by 12%. Constant currency revenue was at $32 million, down by 13% YoY. Sequential quarter sales were at a similar level. Adjusted for one off income in Q1, constant currency de-growth at 9%.

Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 6th in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), vitamins minerals nutritional (VMN) and cosmo-dermatology.

The scrip fell 2.94% to currently trade at Rs 3,045 on the BSE.

Powered by Capital Market - Live News

Net profit of Torrent Pharmaceuticals rose 20.90% to Rs 457.00 crore in the quarter ended June 2024 as against Rs 378.00 crore during the previous quarter ended June 2023. Sales rose 10.48% to Rs 2815.00 crore in the quarter ended June 2024 as against Rs 2548.00 crore during the previous quarter ended June 2023.

Powered by Capital Market - Live News

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 23 July 2024.

Powered by Capital Market - Live News

Torrent Pharmaceuticals announced that the 51th Annual General Meeting (AGM) of the company will be held on 23 July 2024.

Powered by Capital Market - Live News